Literature DB >> 17617844

Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in East Timor.

Tatsuya Fujii1, Koki Kaku, Tomas Jelinek, Mikio Kimura.   

Abstract

BACKGROUND: Malaria poses a significant threat to military personnel stationed in endemic areas; therefore, it is important to examine the risks of military operations, particularly in areas where malaria-related data are scarce. The recent deployment of Japan Ground Self-Defense Force (JGSDF) for a peacekeeping operation in East Timor provided an opportunity to investigate these risks. The results of these studies may be translated into chemoprophylactic strategies for travelers.
METHODS: A total of 1,876 members were deployed between April 2002 and September 2003. They consisted of three battalions; each remained for 6 months and was put on mefloquine prophylaxis. Malaria infection was investigated, including exposure to Plasmodium falciparum sporozoites, assessed by seroconversion for anticircumsporozoite (anti-CS) protein antibodies. Adherence to and adverse events (AEs) of mefloquine were studied via questionnaires.
RESULTS: Four members were evacuated: one each with optic neuritis, lung cancer with brain metastasis, IgA nephropathy, and psychotic reactions that may have been precipitated by mefloquine. Six clinical episodes of Plasmodium vivax occurred, including one relapse, but there were no clinical cases of P falciparum, yielding a crude malaria attack rate of 0.32% for the 6-month period. Overall, 3.1% of the study population seroconverted for the anti-CS protein antibodies, with some regional differences noted. About 24% of questionnaire respondents, reported AEs; however, none of the AEs was severe. The AEs tended to emerge during the initial doses of chemoprophylaxis.
CONCLUSIONS: The implementation of mefloquine prophylaxis among JGSDF personnel in East Timor, where P falciparum constitutes a moderate risk, appears to have been a success. Mefloquine prophylaxis was generally safe for Japanese unless predisposed to neuropsychiatric illness. However, given that mefloquine is the only chemoprophylactic agent available, a risk-benefit analysis tailored to the traveler is required for visits to countries such as East Timor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617844     DOI: 10.1111/j.1708-8305.2007.00122.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  4 in total

1.  Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members.

Authors:  Angelia A Eick-Cost; Zheng Hu; Patricia Rohrbeck; Leslie L Clark
Journal:  Am J Trop Med Hyg       Date:  2016-11-14       Impact factor: 2.345

Review 2.  Compliance with Primary Malaria Chemoprophylaxis: Is Weekly Prophylaxis Better Than Daily Prophylaxis?

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Sumadhya Deepika Fernando
Journal:  Patient Prefer Adherence       Date:  2020-11-09       Impact factor: 2.711

Review 3.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

Review 4.  Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.

Authors:  Stuart McCarthy
Journal:  J Parasitol Res       Date:  2015-12-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.